Rate My Professor Val Gebski

Gebski's academic interests center on advanced statistical methods for clinical trials, including designs addressing competing risks in time-to-event outcomes, biomarker impacts, quality of life (QoL) analyses such as time in good QoL and trade-offs with clinical benefits, toxicity profiles using recurrent time-to-event models with ordinal or multinomial outcomes, and equivalence/non-inferiority studies. His major publications include 'Preoperative Chemoradiotherapy for Resectable Gastric Cancer' in the New England Journal of Medicine (2024), 'Assessing the Potential for Patient-led Surveillance After Treatment of Localized Melanoma (MEL-SELF): A Pilot Randomized Clinical Trial' in JAMA Dermatology (2022), 'Time to Achieve Clinical Important Differences and QoL Profiles' in the Journal of Clinical Oncology (2022), 'Patient-reported outcome measures (PROMs) to guide clinical care: recommendations and challenges' in the Medical Journal of Australia (2022), and 'Lowering the P Value Threshold' in JAMA (2018). With over 35,000 citations across 600+ publications, his work has substantially shaped clinical trial practices and statistical analysis in medicine. He received the Outstanding Contribution Award from the Trans-Tasman Radiation Oncology Group (TROG) for excellence in clinical trial design and statistics.